Company Directory / Biotechnology
Public · FRA:5Y6For profitBiotechnologyAltrincham, United Kingdom
COMPASS Pathways
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.
- Founded
- 2016 10 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $271M as listed, currency not stated
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
10 years old.
Reach
Website ranked #1,951,901 in the world for traffic, about 11k visits a month.
What it does
BiotechnologyHealth CareLife ScienceMental HealthPersonal HealthWellness
Funding, as listed
$271M currency not stated
- Rounds6
- LatestPost ipo equity, Aug 2023
- Investors24, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about COMPASS Pathways, field by field. Contact details are held but never shown.
The company
- Name
- COMPASS Pathways
- Type
- For profit
- Status
- Public · FRA:5Y6
- Founded
- 2016
- Founders
- Ekaterina Malievskaia, George Goldsmith, Lars Christian Wilde
- Industry
- Biotechnology
- Categories
- Biotechnology, Health Care, Life Science, Mental Health, Personal Health, Wellness
Where
- City
- Altrincham
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #1,951,901
- Monthly web visits
- 10,920
Funding, as listed
- Total
- 271,209,674 (currency not stated)
- Rounds
- 6
- Latest round
- Post ipo equity
- Latest round date
- Aug 2023
- Investors
- 24
- Lead investors
- 4
- Stock listing
- FRA:5Y6
- Listing status
- public
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
COMPASS Pathways may be growing as it operates in the psychedelic drug market, which is attracting significant investor interest. The industry is experiencing a surge in investments, as evidenced by the influx of capital into psychedelic drug start-ups focused on mental health treatments. Additionally, the global psychedelic drugs market is projected to reach a value of USD 8.7 billion by 2033, growing at a CAGR of 11.61%, indicating a positive outlook for companies like COMPASS Pathways that are part of this sector. Furthermore, the legal landscape around psilocybin mushrooms, which are relevant to COMPASS Pathways' field, is a topic of discussion, suggesting a growing interest and potential for market expansion.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.